Compare 3M Company (MMM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs BIO-TECHNE Corp — how do they compare? 3M Company trades at $163.61 (market cap $84.36B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: 3M Company is far larger — about 7.4× BIO-TECHNE Corp's market cap, and 3M Company pays the higher dividend (1.91%). Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and BIO-TECHNE Corp for 63 Days on average.
| MMM | TECH | |
|---|---|---|
Market Cap | $84.36B | $11.36B |
Volume | 2,325,301 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $183.79 | $72.61 |
52-Week Low | $141.10 | $43.31 |
Typical Hold Time | 169 Days | 63 Days |
Enterprise Value | $93.58B | $11.39B |
Dividend Yield | 1.91% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMM trades at $162.12, down 0.93% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a robust net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while recent news highlights operational turnaround progress and litigation management.
The outlook balances solid fundamentals against high debt and weak consumer demand. Upside potential exists from industrial strength and shareholder returns, but risks include cost pressures and macroeconomic headwinds. The stock's current valuation at a P/E of 28.8 requires sustained earnings growth to justify further gains.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
